The demand for PSE-containing
cold, allergy, and sinus products is growing due to their effectiveness and
convenience. PSE is an active ingredient found in various cold, allergy, and
sinus drugs that can provide congestion relief. However, PSE-containing
medicines are mostly sold as a prescription drug, as PSE can also be used for
the illegal manufacture of methamphetamine, a recreational drug. This has led
drug manufacturers to produce tamper-resistant PSE products. For instance, in
March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe
Pharmaceuticals LLC entered into an agreement, enabling MainPointe
Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and
Canada. These drugs utilize tamper-resistant PSE formulation to prevent the
illicit production of methamphetamine.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL RESPIRATORY DRUGS MARKET TO GROW TO $73 BILLION
BY 2021
North America was the largest
region in the respiratory diseases drugs market in 2017, accounting for half of
the market share. This was mainly due to high number of patients with
respiratory diseases, more people covered under medical insurance programs and higher
pricing of medications in the USA.
Order the report at https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018
The chart below shows the
year-on-year growth of the global respiratory drugs market during 2017 – 2021
According to The Business Research
Company’s Consultant, Nitin Gianchandani,
pharmaceutical companies are focusing on nasal remedies owing to growing
consumer demand for these products. Nasal remedies for cold include sprays,
drops or inhalers such as nasal spray, saline spray, steroid spray,
antihistamine spray, and nose drops. These remedies work faster than
traditional drugs and these products are generally sold over-the-counter (OTC).
Download a sample of the report
at:
GlaxoSmithKline was the largest
company in the respiratory disorder drugs market in 2017, generating revenues
of $13.2 billion for the financial year 2016. The company’s strategy involves
increasing investments in R&D to drive discovery and development in
respiratory diseases drugs. In 2016, GSK filed Closed Triple therapy for
chronic obstructive pulmonary disease (COPD) for regulatory approval in Europe
and the US. The company has also in-licensed anti-IL33R antibody for severe
asthma, and danirixin is into phase IIb clinical development for treating
patients with COPD.
The respiratory diseases drugs
market covers drugs that are used in the treatment of a wide range of
respiratory diseases such as asthma, chronic obstructive pulmonary disease
(COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of
the major drugs in the market include antimuscarinics, corticosteroids,
Codral®, Coldrex® and Lemsip®.
Respiratory Diseases Drugs Global
Market Report 2018 is a detailed report giving a unique insight into this
market. The report is priced at $4000 for an individual user. To use across
your office, the price is $6000 and $8000 if you wish to use across a
multinational company.
About The Business Research Company:
Visit TheBusinessResearchCompany.com,
mail info@tbrc.info or call +447443439350 or
+918897263534 or +919160996838 for more information on this and many other
titles.
The Business Research Company is a
market research and intelligence company, which excels in company, market and
consumer research.
It has research professionals at its
offices in the UK, India and the US as well a network of trained researchers
globally. It has specialist consultants in a wide range of industries including
manufacturing, healthcare, chemicals and technology.
The Business Research Company's
management has more than 20 years of varied business research experience. They
have delivered hundreds of research projects to the senior management of some
of the world's largest organizations.
Contact Information:
The
Business Research Company
Europe:
+44 207 1930 708
Asia:
+91 8897263534
Americas:
+1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment